Pegvisomant-Induced Lipohypertrophy: Report of a Case with Histopathology
Authors: Monica Marazuela, Esteban Daudén, Elena Ocón, Dolores Moure, Lia Nattero
Journal: Annals of Internal Medicine (2007)

Letters20 November 2007Pegvisomant-Induced Lipohypertrophy: Report of a Case with HistopathologyMonica Marazuela, MD, PhD, Esteban Daudén, MD, PhD, Elena Ocón, MD, Dolores Moure, MD, and Lia Nattero, MDMonica Marazuela, MD, PhDFrom Hospital de la Princesa, Universidad Autónoma, Madrid 28006, Spain., Esteban Daudén, MD, PhDFrom Hospital de la Princesa, Universidad Autónoma, Madrid 28006, Spain., Elena Ocón, MDFrom Hospital de la Princesa, Universidad Autónoma, Madrid 28006, Spain., Dolores Moure, MDFrom Hospital de la Princesa, Universidad Autónoma, Madrid 28006, Spain., and Lia Nattero, MDFrom Hospital de la Princesa, Universidad Autónoma, Madrid 28006, Spain.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-147-10-200711200-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: In a recent report, Maffei and colleagues (1) described 2 patients who developed subcutaneous lipohypertrophy in the abdomen during pegvisomant therapy (Somavert, Pfizer, New York).Objective: To describe the effect of pegvisomant-induced lipohypertrophy on insulin-like growth factor I (IGF-I) levels.Case Report: A 50-year-old woman with active acromegaly was prescribed subcutaneous pegvisomant, 10 mg/d, after a lack of response to somatostatin analogues. After 2 months of therapy, IGF-I levels reached the low normal range (Figure 1). After 4 months of therapy, IGF-I returned to pretreatment levels. The IGF-I levels did not reach the normal range despite the pegvisomant dose ...References1. Maffei P, Martini C, Pagano C, Sicolo N, Corbetti F. Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant [Letter]. Ann Intern Med. 2006;145:310-2. [PMID: 16908925] LinkGoogle Scholar2. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342:1171-7. [PMID: 10770982] CrossrefMedlineGoogle Scholar3. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358:1754-9. [PMID: 11734231] CrossrefMedlineGoogle Scholar4. Raile K, Noelle V, Landgraf R, Schwarz HP. Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes. 2001;109:393-6. [PMID: 11748486] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Hospital de la Princesa, Universidad Autónoma, Madrid 28006, Spain.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoLipohypertrophy in Acromegaly Induced by the New Growth Hormone Receptor Antagonist Pegvisomant Pietro Maffei , Chiara Martini , Claudio Pagano , Nicola Sicolo , and Francesco Corbetti Metrics Cited ByBody Composition Changes with Long-term Pegvisomant Therapy of AcromegalyPegvisomant in acromegaly: an updateLipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear?Improvement of Insulin Injection TechniqueInsulin Shot Dependent Lipodystrophy: Evidence, Uncertainties and Current Terminology OverlapsLong-term treatment with pegvisomant for acromegaly: a 10-year experienceEscape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish studyClinical and radiological evidence of the recurrence of reversible pegvisomant-related lipohypertrophy at the new site of injection in two women with acromegaly: a case seriesDG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumoursSelf-limited acute hepatotoxicity caused by pegvisomantGHR Antagonist: Efficacy and SafetyACROSTUDY: the first 5 yearsSubcutaneous lipoatrophy induced by long-term pegvisomant administrationLong-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapyLipodystrophy in Patients with Acromegaly Receiving PegvisomantPegvisomant 20 November 2007Volume 147, Issue 10Page: 741-743KeywordsAdipocytesAntibodiesBiopsyCellsFatsGrowth hormoneInsulin-like growth factorsNecrosisPatient advocacySomatostatin ePublished: 20 November 2007 Issue Published: 20 November 2007 CopyrightCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...